SubsidieMeestersBioProtect Balloon Implant System – Enabling Safe Prostate Radiation Treatment even at extreme dosage
ProSpace is a biodegradable balloon spacer that protects rectal tissue during prostate cancer radiation treatment by creating a safe distance between the prostate and rectum.
Projectdetails
Introduction
Prostate is the 2nd leading cancer in men in the world, with more than 1.4 million men diagnosed every year globally. Approximately 50% of men will be treated with radiation treatment.
Radiation Treatment and Complications
Radiation is a highly effective treatment; however, it has significant complications, mainly injuring the rectal tissue, which is adjacent to the prostate treatment area.
Side Effects
Up to 35% of the patients will experience rectal toxicity side effects, which include:
- Bleeding
- Urinary dysfunction
- Bowel dysfunction
- Erectile dysfunction
These side effects can severely damage patients' quality of life. There is a growing need for a solution that protects the rectum from the radiation field.
Solution: ProSpace
Our solution, ProSpace, is a biodegradable medical-grade copolymer (70:30 Poly L-Lactide-co-Caprolactone) balloon spacer deployed in the prostate-rectum interspace.
Benefits of ProSpace
It creates a 1.8 cm symmetric distance between the prostate and rectum, allowing physicians to:
- Radiate prostate tumors
- Spare healthy rectal tissue
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.501.632 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- BIOPROTECT LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsyThe Selio System aims to prevent pneumothorax during lung biopsies by pre-sealing the needle tract, enhancing patient safety and reducing healthcare costs. | EIC Accelerator | € 2.499.999 | 2022 | Details |
A natural breast for cancer survivors: resorbable implant supporting tissue regenerationREGENERA aims to provide lumpectomy patients with a resorbable implant that promotes natural breast restoration through tissue self-regeneration, minimizing pain and follow-up surgeries. | EIC Accelerator | € 2.498.600 | 2023 | Details |
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumoursPadeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry. | EIC Accelerator | € 2.498.730 | 2024 | Details |
LIACFLASH: a life changing IOeRT technology for oncology careLIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue. | EIC Accelerator | € 2.499.962 | 2022 | Details |
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.
Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsy
The Selio System aims to prevent pneumothorax during lung biopsies by pre-sealing the needle tract, enhancing patient safety and reducing healthcare costs.
A natural breast for cancer survivors: resorbable implant supporting tissue regeneration
REGENERA aims to provide lumpectomy patients with a resorbable implant that promotes natural breast restoration through tissue self-regeneration, minimizing pain and follow-up surgeries.
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
Padeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry.
LIACFLASH: a life changing IOeRT technology for oncology care
LIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
PROstate Focal THerapyThe PROFTH project aims to advance prostate cancer focal therapies by developing robotics and AI for precise ablation device positioning, enhancing treatment safety and efficacy. | ERC Proof of... | € 150.000 | 2024 | Details |
SupraTagEen innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen. | Mkb-innovati... | € 200.200 | 2020 | Details |
Portal Range Monitoring in Mixed Ion Beam SurgeryPROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
PROstate Focal THerapy
The PROFTH project aims to advance prostate cancer focal therapies by developing robotics and AI for precise ablation device positioning, enhancing treatment safety and efficacy.
SupraTag
Een innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen.
Portal Range Monitoring in Mixed Ion Beam Surgery
PROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.